In partnership with MT Pharma America, MDA will host a July 12 webinar at 3 p.m. Eastern time that will provide ALS families with information about Radicava. MT Pharma will discuss Radicava’s development, as well as help to prepare families for when the drug will be available. At the end, there will be time for a Q&A session where participants will be asked to provide questions to the moderator via the webinar chat function.
The webinar is open to the first 500 callers (including those calling in with their computer). A recording will be available after July 12 on mda.org.
Instructions to join the webinar
- Click here to join the webinar.
- Click “Join Now” and allow the meeting time to load.
- After you log in, use the phone number, access code and attendee ID that pops up on your screen. You must have an attendee ID to attend.
Need to call in using your computer? Select the “call using computer” option and your speakers and microphone will be activated. If you don’t have a microphone, you can listen in and view the presentation and provide questions to the moderator via the chat function.
On May 5, the U.S. Food and Drug Administration (FDA) approved edaravone (brand name Radicava) for the treatment of ALS (amyotrophic lateral sclerosis). It’s the first drug to be granted FDA approval to treat ALS in the United States in more than 20 years.
Radicava is thought to work by relieving the effects of oxidative stress, which has been suspected to play a role in the death of nerve cells called motor neurons in people with ALS. (Oxidative stress is an imbalance between the production of free radicals and the ability of the body to counteract or detoxify their harmful effects with antioxidants.) Targeting this pathway could potentially preserve motor neuron health, which could in turn keep muscles functional for a longer period of time.